Inhibit progression of coronary artery calcification with vitamin K in hemodialysis patients (the iPACK-HD study): a randomized, placebo-controlled multi-center, pilot trial. Issue 3 (31st May 2022)

• Record Type: Journal Article
• Authors: Holden, Rachel M; Booth, Sarah L; Zimmerman, Deborah; Moist, Louise; Norman, Patrick A; Day, Andrew G; Menard, Alex; Fu, Xueyan; Shea, M Kyla; Babiolakis, Corinne S; Nolan, Robert; Turner, Mandy E; Ward, Emilie; Kaufmann, Martin; Adams, Michael A; Heyland, Daren K
• Is Part Of: Nephrology dialysis transplantation. Volume 38:Issue 3(2023)
• Page Start: 746
• Page End: 756
• Publication Date: 2022-05-31
• Subjects: chronic kidney disease -- coronary artery calcification -- phylloquinone -- randomized pilot -- vitamin K; Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfac191
• Languages: English
• ISSNs: 0931-0509

Abstract

ABSTRACT: Background: Vitamin K activates matrix Gla protein (MGP), a key inhibitor of vascular calcification. There is a high prevalence of sub-clinical vitamin K deficiency in patients with end-stage kidney disease. Methods: A parallel randomized placebo-controlled pilot trial was designed to determine whether 10 mg of phylloquinone thrice weekly versus placebo modifies coronary artery calcification progression over 12 months in patients requiring hemodialysis with a coronary artery calcium score (CAC) ≥30 Agatston Units (ClinicalTrials.gov identifier NCT01528800). The primary outcome was feasibility (recruitment rate, compliance with study medication, study completion and adherence overall to study protocol). CAC score was used to assess calcification at baseline and 12 months. Secondary objectives were to explore the impact of phylloquinone on vitamin K-related biomarkers (phylloquinone, dephospho-uncarboxylated MGP and the Gla-osteocalcin to Glu-osteocalcin ratio) and events of clinical interest. Results: A total of 86 patients with a CAC score ≥30 Agatston Units were randomized to either 10 mg of phylloquinone or a matching placebo three times per week. In all, 69 participants (80%) completed the trial. Recruitment rate (4.4 participants/month) and medication compliance (96%) met pre-defined feasibility criteria of ≥4.17 and ≥90%, respectively. Patients randomized to phylloquinone for 12 months had significantly reduced levels of dephospho-uncarboxylated MGP (86% reduction) and increased levels of phylloquinone and Gla-osteocalcin to Glu-osteocalcin ratio compared with placebo. There was no difference in the absolute or relative progression of coronary artery calcification between groups. Conclusion: We demonstrated that phylloquinone treatment improves vitamin K status and that a fully powered randomized trial may be feasible. Graphical Abstract: